Introduction
Non-small cell lung cancer (NSCLC) is a serious threat to the health of all mankind and accounts for ~80% of all lung cancers. 1 Surgical resection is a common treatment for NSCLC, but surgery cannot completely prevent tumor proliferation, and it also has some adverse effects on tumor cells. 2 The effects of anesthetics and anesthesia techniques can possibly affect the longterm outcome of patients who have undergone cancer surgery. 3 The volatile anesthetic sevoflurane is widely used in surgery as there is extensive clinical data supporting its safety. 4 Over the years, there has been a growing interest in the biological effects of sevoflurane on tumor and organ systems and the molecular mechanisms involved. The antiproliferative and anti-invasive effects of sevoflurane have been demonstrated on some cancer cells. 5, 6 miRNA is estimated to control 30%-90% of human genes. 7 miRNA has a specific expression profile in lung cancer and participates in the whole process of lung cancer development. 8 In a previous study, it was found that sevoflurane affects the expression of miRNAs in normal rat lung. 9 However, whether sevoflurane interferes with the miRNA of lung submit your manuscript | www.dovepress.com
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Materials and methods cell line and cell culture
A549, the human pulmonary adenocarcinoma cell line, was obtained from Shanghai R&S Biotechnology Co., Ltd (Shanghai, People's Republic of China), and maintained in Roswell Park Memorial Institute-1640 supplemented with 10% fetal bovine serum, 100 µg/mL streptomycin, and 100 U/mL penicillin. The cells were incubated in 5% CO 2 humidified at 37°C for growth.
A549 cell exposure to sevoflurane
The cells were kept in a sealed container which was always moistened to 37°C. Sevoflurane was carried by 0.5 L/min mixture of 95% air and 5% carbon dioxide through the volatilization tank (Drager, Lübeck, Germany). The concentration of anesthetic gas was monitored by a gas monitor (PM8050, Drager) at the outlet of the closed box, and the calibration of the volatile tank was adjusted to keep the concentration at 3%. The sevoflurane group was treated for 30 minutes. The control group was also in the same incubator for the same culture, but was given a mixture of 95% air and 5% carbon dioxide, without sevoflurane.
Quantitative real time polymerase chain reaction (qrT-Pcr)
Total RNA was extracted using Trizol reagent (Life Technologies, Carlsbad, CA, USA) for miRNA34a, miRNA155, miRNA146a, miRNA21, miRNA223, and miRNA221 analyses. For miRNA analysis, cDNA was synthesized using Bulge-Loop™ miRNA qRT-PCR Primer Set (All-in-One™ miRNA First-Strand cDNA Synthesis Kit; Gene Copoeia, Rockville, MD, USA) according to the manufacturer's instructions, normalized to that of U6 of the same RNA. Quantitative PCR was carried out using SYBR Premix Ex Taq™ (All-in-One™ miRNA qPCR Kit; GeneCopoeia, Inc., Rockville, MD, USA) according to the manufacturer's protocol. Relative expression was evaluated by comparative CT method and normalized to the expression of U6 small RNA. The target gene was quantified relative to the control gene and is expressed as fold change, calculated as 2
Apoptosis analysis by annexin V/PI flow cytometry A549 cells were cultured in 12-well plates (1×10 5 cells/well). After 3% sevoflurane treatment for 30 minutes, cells were placed in CO 2 incubator for an additional 2 days of culture. After that, the percentage of cell apoptosis was detected by flow cytometry analysis using an Annexin V-FITC Apoptosis Kit (Sungene Biotech Co., Ltd, Tianjin, People's Republic of China). Cells were washed twice with cold PBS, and resuspended in 400 µL with 1× binding buffer at a concentration of 1×10 6 cells/mL. This binding buffer was supplemented with 5 µL of annexin V-FITC and incubated at room temperature in the dark for 15 minutes. Ten microliter of PI was then added and incubated at 4°C in the dark for 5 minutes. Cells were analyzed by a flow cytometer (BD FASAria Cell Sorter, BD Biosciences, Franklin Lakes, NJ, USA) within 1 hour.
statistical analysis
Statistical analysis was performed using SPSS software 13.0 (SPSS Inc., Chicago, IL, USA). Values are expressed as the means ± SD. The significance of between-group differences was assessed using analysis of variance followed by Dunnett's test. P-values ,0.05 were considered to indicate statistically significant differences.
Results
Sevoflurane promotes apoptosis of A549 cells
To observe the effect of sevoflurane on the apoptosis of A549 cells, we analyzed the cells using flow cytometry. As shown in Figure 1 , 3% sevoflurane was able to significantly decrease the number of A549 cells compared with control group, and apoptosis rate increased significantly (P,0.05).
expression of mirna
qRT-PCR analysis showed that all 6 miRNAs changed. Relative expression ratios of miRNAs compared to the control group are presented in Figure 2 . In the sevoflurane group, miR-21, miR-146a, miR-221, and miR-223 showed marked increases (P,0.05). Compared to the control group, the expression of miR-34a and miR-155 decreased significantly in the sevoflurane group (P,0.05).
Discussion
For NSCLC, the overall 5-year survival rate remains poor. 10 Surgery is an effective method for the treatment of NSCLC. Sevoflurane was synthesized in the early 1970s, but was not released for clinical use until the early 1990s. It has been accepted worldwide as a safe and reliable anesthetic agent for clinical practice in various settings. Sevoflurane is a colorless, volatile, and nonflammable liquid with a characteristic smell. During sevoflurane anesthesia, bronchi, pulmonary alveoli, and tumor are directly exposed to sevoflurane.
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Sevoflurane has some protective effects on the respiratory system, provides bronchodilation, and attenuates bronchial smooth muscle constriction by histamine or acetylcholine and can be safely used in patients with asthma. Recent studies have found that 4% sevoflurane can modulate the expression of mRNAs and miRNAs in rat lungs, and then attenuate the toxic effects associated with lipopolysaccharide stimulation. The aim of our study was to elucidate the effect of sevoflurane on the miRNAs of lung cancer cells. We pretreated A549 cells for 30 minutes to simulate the clinical anesthesia setting. It has been confirmed that surgical operation can enhance the invasion and migration potential of cancer cells, thus improving its ability to spread during perioperative period. Cancer is marked by 6 hallmarks, one of which is resisting cell death. 11 Our study found that 3% sevoflurane-pretreated A549 cells, for a duration of 30 minutes, that is, before surgery, caused an increase in the rate of cancer cell apoptosis, which greatly reduced the risk of cancer cell metastasis in the operation and increased the postoperative survival rate of the patients, which is similar to results of previous studies on sevoflurane. 12, 13 Because of their wide variety of targets, miRNAs have been found to affect numerous developmental processes within cells including hematopoietic lineage differentiation, immunity, inflammation, and tumorigenesis. miRNAs in lung cancer cells include two major categories: oncogenic miRNAs and suppressive miRNAs. We selected three types of tumor suppressive miRNAs (miR-21, miR-221, and miR-155) and three oncogenic miRNAs (miR-146a, miR-223, and miR-34a), and they are all related to the apoptosis of cancer cells.
Some studies have shown that miR-155 upregulates Mxd1/Mad1, a network of basic helix-loop-helix leucine zipper transcription factors which mediate cellular apoptosis, through regulating BCL6. In this way, miR155 leads to the resistance of cell death and enables replicative immortality. 14 Jeon et al 15 observed that the rs2910164CNG in pre-miR146a may contribute to genetic susceptibility to lung cancer. 16 miR-223 functions as a tumor suppressor, which may finetune the activity of the IGF-1R pathway in lung cancer. 17 These miRNAs are all associated with apoptosis of lung cancer cells. Our study found that 3% of sevoflurane preconditioning for 30 minutes did play a positive role, ie, increased the apoptosis rate of cancer cells, and that the three miRNAs (miRNA155, 146a, and 223) changed. Patients receiving sevoflurane pretreatment before surgery can indeed reduce the risk of cancer cell proliferation and metastasis during surgery. Although many documents [14] [15] [16] [17] suggest that these miRNA can regulate the apoptosis of lung cancer cells in a variety of ways, further study is needed on whether sevoflurane can increase apoptosis through these miRNA.
Chakraborty found that high expression of miR-34a in A549 and H1299 cells in NSCLC cells could significantly inhibit the expression of Bcl-2. 18 Research has shown that miR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis. 19 Garofalo et al 20 reported that additional targets of miRNAs 221, such as PETN/TIMP3 21 and PUMA (also known as Bcl-2 binding component 3), 22 seem to mediate TRAIL resistance, migration, and invasiveness, thus correlating with the frequent overexpression of these miRNAs in epithelial cancers, including lung cancers. 23 However, after the treatment of A549 cells with 3% sevoflurane, the changes of miRNAs (34a, 221, 21) were different from what we expected, and from the previous experience on the impact of these miRNAs on cancer cells, the result should be the increase of cancer cells, but our result is that the apoptosis of cancer cells is increasing. Therefore, from our results, 3% sevoflurane-pretreated A549 cells can indeed change the miRNAs in cancer cells and increase the apoptosis of cancer cells. Although these miRNAs are related to the regulation of cancer cell apoptosis, the effects of sevoflurane on miRNAs seem to be irregular, that is to say, sevoflurane appears to randomly alter those miRNAs that regulate apoptosis, but the final result is the increase of cancer cell apoptosis. Of course, the number of miRNAs we studied was not enough to fully explain this phenomenon. More miRNAs need to be studied. It is necessary to further study whether sevoflurane can increase the apoptosis of cancer cells through the regulation of miRNAs, or assess if it just disrupts the miRNAs in A549 cells.
In conclusion, the results from our study revealed that 3% sevoflurane pretreatment of A549 cells for 30 minutes can change several kinds of apoptosis-related miRNAs, increase the apoptosis rate of lung cancer cells, and reduce the number of cancer cells.
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